Scholars Central

Research articlePublished 10 Jan 2023

The Effect of Adjuvants and Immune Routes on the Immunodominance of Epitopes and Protection Efficacy of SARS-CoV-2 RBD Antigen

Authors: Sisi Li, Lianli Duan, Xiaoli Zhang, Rui Yang, Longlong Chen, Zhifu Chen, Qiang Gou, Wenxin Bao, Yue Yuan, Haiming Jing, Yi Zhang, Ping Cheng, Ping Luo, Li Ni, Wanneng Wang, Zhuo Zhao

Immunotherapy: Open Access

Volume 9 · Issue 1 · Pages 1–10

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Previous studies have revealed that the Receptor-Binding Domain (RBD) of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein is immunogenic in both mice and healthy volunteers, and humoral immune response plays a key role in RBD-mediated protection. In this study, we investigated the immunogenicity and protective efficacy of immunization with RBD plus three different adjuvants (Al(OH)3, ASO3, and AddaVax) against SARS-CoV-2 pseudo virus through two different routes (intramuscular or intranasal immunization) in mice. The results showed that the immunogenicity and titer of neutralizing antibodies changed in response to different adjuvants and immune routes. Furthermore, six B-cell immunodominant epitopes (RBD1-18, RBD49-66, RBD61-78, RBD97-114, RBD139-156, and RBD145-162) in RBD were identified using antisera from a different immunized group, which may explain the differences in protection observed in each immunized group. Through sequence alignment, we found that six B-cell epitopes are highly conserved among different SARS-COV-2 variants (including Alpha-, Beta-, Gamma- and Omicron-Variant). This study indicated that the immunodominance of epitopes and protection efficacy of RBD antigen are different by different adjuvants and immune routes, which may further guide adjuvant screening for vaccine development and optimization.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Immunotherapy: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunotherapy: Open Access
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Sisi Li”
  • BylineArticles whose byline prints “Lianli Duan”
  • BylineArticles whose byline prints “Xiaoli Zhang”
  • BylineArticles whose byline prints “Rui Yang”
  • BylineArticles whose byline prints “Longlong Chen”
  • BylineArticles whose byline prints “Zhifu Chen”
  • BylineArticles whose byline prints “Qiang Gou”
  • BylineArticles whose byline prints “Wenxin Bao”